Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New stroke treatment could help patients with medium-artery blockages

NCT ID NCT07347665

Disease control Sponsor: Hyogo Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study looks at whether removing a blood clot from a medium-sized brain artery (M2 segment) helps people recover better after a stroke. About 200 adults who have had a stroke and are not helped by clot-busting medicine will be randomly assigned to get either standard care or standard care plus a procedure to remove the clot. The main goal is to see if more people can live independently 90 days later.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Mar 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 84 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Acute cerebral infarction 2. Aged 18-84 years 3. NIHSS score at admission ≥ 8 4. Prestroke mRS scores of 0-1 (able to carry out all usual activities) 5. Occlusion of the M2 segment of MCA on digital subtraction angiography 6. ASPECTS ≥ 8 or DWI-ASPECTS ≥ 8 7. Ineligible or failed intravenous tPA (no recanalization within 30 min after injection) 8. Randomization can be completed within 24 h from the last known well time 9. EVT can be initiated within 30 min from randomization. 10. The patient or their legally authorized representative has signed the informed consent form. Exclusion Criteria: 1. Occlusion of the anterior temporal artery, duplicate M1, or accessory M1 2. Occlusion of multiple major intracranial arteries 3. Difficulty in endovascular access due to tortuous vascular anatomy 4. Significant mass effect with midline shift on CT (or MRI) 5. Known allergy (more severe than skin rash) to contrast agents 6. Evidence of acute intracranial hemorrhage on CT (or MRI) 7. Pregnant or potentially pregnant 8. Clinical evidence of chronic occlusion 9. High risk of hemorrhage (platelet \< 40,000/ul, APTT \> 50 sec or PT-INR \> 3.0) 10. Participating in any other therapeutic investigational trial 11. Judgment of the investigator to be non-compliant or uncooperative during the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute ischemic stroke are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cerebral artery occlusion ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute ischemic stroke Acute ischemic stroke (AIS) related to A distal occlusion Endovascular therapy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hyogo Medical University

    RECRUITING

    Nishinomiya, Hyōgo, 663-8501, Japan

  • S.I.S Can Tho International General Hospital

    RECRUITING

    Can Tho, Can Tho City, 94118, Vietnam

  • Thammasat University Hospital

    RECRUITING

    Khlong Luang, Changwat Pathum Thani, 12120, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.